Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib and Sintilimab for Neoadjuvant Therapy in Locally Advanced Thyroid Cancer
NCT06787911Phase 2Recruiting
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib, sintilimab in differentiated thyroid carcinoma (DTC). Started Jul 2024; status: recruiting.
02
Drugs
donafenibsintilimab
03
Conditions
differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT06787911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06787911.